King's College London

Research portal

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

Research output: Contribution to journalArticle

Sabine Kayser, Robert K. Hills, Marlise R. Luskin, Andrew M. Brunner, Christine Terré, Jörg Westermann, Kamal Menghrajani, Carole Shaw, Maria R. Baer, Michelle A. Elliott, Alexander E. Perl, Zdeněk Ráčil, Jiri Mayer, Pavel Zak, Tomas Szotkowski, Stéphane de Botton, David Grimwade, Karin Mayer, Roland B. Walter, Alwin Krämer & 13 more Alan K. Burnett, Anthony D. Ho, Uwe Platzbecker, Christian Thiede, Gerhard Ehninger, Richard M. Stone, Christoph Röllig, Martin S. Tallman, Elihu H. Estey, Carsten Müller-Tidow, Nigel H. Russell, Richard F. Schlenk, Mark J. Levis

Original languageEnglish
Pages (from-to)161-169
Number of pages9
Issue number1
Early online date19 Apr 2019
Publication statusPublished - 1 Jan 2020


King's Authors


Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation (allo-HCT) may improve survival if performed early during first complete remission. We report on a cohort of 178 patients with t(6;9)(p22;q34) within an international, multicenter collaboration. Median age was 46 years (range: 16-76), AML was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. Complete remission was achieved in 81% (n=144), including 14 patients who received high-dose cytarabine after initial induction failure. With a median follow up of 5.43 years, estimated overall survival at five years was 38% (95%CI: 31-47%). Allo-HCT was performed in 117 (66%) patients, including 89 in first complete remission. Allo-HCT in first complete remission was associated with higher 5-year relapse-free and overall survival as compared to consolidation chemotherapy: 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%) versus 7% (95%CI: 3-19%) and 23% (95%CI: 13-38%), respectively. For patients undergoing allo-HCT, there was no difference in overall survival rates at five years according to whether it was performed in first [53% (95%CI: 42-66%)], or second [58% (95%CI: 31-100%); n=10] complete remission or with active disease/relapse [54% (95%CI: 34-84%); n=18] (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclusion, outcomes of t(6;9)(p22;q34) AML are poor with chemotherapy, and can be substantially improved with allo-HCT.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454